Association between updated guideline-based palivizumab administration and hospitalizations for respiratory syncytial virus infections

Pediatric Infectious Disease Journal

Volumn 35, Issue 7, 2016, Pages 728-732

  Grindeland, Carlina J ^a   Mauriello, Clifford T ^a   Leedahl, David D ^a   Richter, Lisa M ^a   Meyer, Anne C ^a  

^a Sanford Health Medical Center   (United States)

Author keywords

bronchiolitis; hospitalization; infant; palivizumab; pediatric; respiratory infection; respiratory syncytial virus; Synagis

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; HEALTH SURVEY; NEWBORN; NORTH DAKOTA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; NORTH DAKOTA; PALIVIZUMAB; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84963604214     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001150     Document Type: Article

References (27)

1. Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 2014;6:217-225.
2. Centers for Disease Control and Prevention. RSV: infection and incidence. January 2010. Available at: http://www.cdc.gov/rsv/about/infection.html. Accessed August 26, 2014.
3. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30:510-517.
4. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-598.
5. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
6. Huang K, Incognito L, Cheng X, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010;84:8132-8140.
7. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics. 1998;102:1211-1216.
8. American Academy of Pediatrics. In: Pickering LK ed. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012:609.
9. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415-420.
10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 pt 1): 531-537.
11. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virusassociated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341-e348.
12. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154:55-61.
13. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865-870.
14. Winterstein AG, Knox CA, Kubilis P, et al. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr. 2013;167:1118-1124.
15. Feltes TF, Cabalka AK, Meissner HC, et al; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
16. Chang RK, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol. 2010;31:90-95.
17. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002;156:1034-1041.
18. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.
19. Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12:iii, ix-iiix, 1.
20. Weiner LB, Masaquel AS, Polak MJ, et al. Cost-effectiveness analysis of palivizumab among pre-Term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15:997-1018.
21. Mahadevia PJ, Masaquel AS, Polak MJ, et al. Cost utility of palivizumab prophylaxis among pre-Term infants in the United States: a national policy perspective. J Med Econ. 2012;15:987-996.
22. Meissner HC, Kimberlin DW. RSV immunoprophylaxis: does the benefit justify the cost?. Pediatrics. 2013;132:915-918.
23. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-1701.
24. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620-e638.
25. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-1928.
26. Blanken MO, Rovers MM, Molenaar JM, et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-1799.
27. Henderson FW, Collier AM, Clyde WA Jr, et al. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979;300:530-534.